Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ingeborg Zehbe

Showing results (31-40 of 54) with videos related to

Pageof 6
Sort By:
Health Education Journal|November 22, 2016
Teaching tools to engage Anishinaabek First Nations women in cervical cancer screening: Report of an educational workshopIngeborg Zehbe, Brianne Wood, Pamela Wakewich, et al.
Journal of Therapeutic Ultrasound|November 10, 2015
Sonoporation efficacy on SiHa cells in vitro at raised bath temperatures-experimental validation of a prototype sonoporation deviceJonathan Kivinen, Melissa Togtema, Gregor Mulzer, et al.
Antiviral Therapy|June 21, 2011
Lopinavir up-regulates expression of the antiviral protein ribonuclease L in human papillomavirus-positive cervical carcinoma cellsGavin Batman, Anthony W Oliver, Ingeborg Zehbe, et al.
Nanomedicine (London, England)|February 1, 2018
Synthetic siRNA targeting human papillomavirus 16 E6: a perspective on in vitro nanotherapeutic approachesMelissa Togtema, Robert Jackson, Jessica Grochowski, et al.
International Journal of Molecular Sciences|May 1, 2019
Single-Domain Antibodies Represent Novel Alternatives to Monoclonal Antibodies as Targeting Agents against the Human Papillomavirus 16 E6 ProteinMelissa Togtema, Greg Hussack, Guillem Dayer, et al.
Women'S Health Issues : Official Publication of the Jacobs Institute of Women'S Health|September 3, 2013
A qualitative study of provider perspectives of structural barriers to cervical cancer screening among first nations womenMarion Maar, Ann Burchell, Julian Little, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 15, 2006
Increased risk for cervical disease progression of French women infected with the human papillomavirus type 16 E6-350G variantMartha Grodzki, Guillaume Besson, Christine Clavel, et al.
Journal of Medical Virology|September 15, 2007
Activities of human papillomavirus 16 E6 natural variants in human keratinocytesYulia Asadurian, Helena Kurilin, Hava Lichtig, et al.
Health Care for Women International|November 7, 2014
Strategies for Increasing Cervical Cancer Screening Amongst First Nations Communities in Northwest Ontario, CanadaMarion Maar, Pamela Wakewich, Brianne Wood, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|May 19, 2010
IFN-κ, a novel type I IFN, is undetectable in HPV-positive human cervical keratinocytesCorrene A DeCarlo, Alberto Severini, Lutz Edler, et al.
Pageof 6

Showing results (31-40 of 54) with videos related to

Sort By:
Pageof 6
Health Education Journal|November 22, 2016
Teaching tools to engage Anishinaabek First Nations women in cervical cancer screening: Report of an educational workshopIngeborg Zehbe, Brianne Wood, Pamela Wakewich, et al.
Journal of Therapeutic Ultrasound|November 10, 2015
Sonoporation efficacy on SiHa cells in vitro at raised bath temperatures-experimental validation of a prototype sonoporation deviceJonathan Kivinen, Melissa Togtema, Gregor Mulzer, et al.
Antiviral Therapy|June 21, 2011
Lopinavir up-regulates expression of the antiviral protein ribonuclease L in human papillomavirus-positive cervical carcinoma cellsGavin Batman, Anthony W Oliver, Ingeborg Zehbe, et al.
Nanomedicine (London, England)|February 1, 2018
Synthetic siRNA targeting human papillomavirus 16 E6: a perspective on in vitro nanotherapeutic approachesMelissa Togtema, Robert Jackson, Jessica Grochowski, et al.
International Journal of Molecular Sciences|May 1, 2019
Single-Domain Antibodies Represent Novel Alternatives to Monoclonal Antibodies as Targeting Agents against the Human Papillomavirus 16 E6 ProteinMelissa Togtema, Greg Hussack, Guillem Dayer, et al.
Women'S Health Issues : Official Publication of the Jacobs Institute of Women'S Health|September 3, 2013
A qualitative study of provider perspectives of structural barriers to cervical cancer screening among first nations womenMarion Maar, Ann Burchell, Julian Little, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|April 15, 2006
Increased risk for cervical disease progression of French women infected with the human papillomavirus type 16 E6-350G variantMartha Grodzki, Guillaume Besson, Christine Clavel, et al.
Journal of Medical Virology|September 15, 2007
Activities of human papillomavirus 16 E6 natural variants in human keratinocytesYulia Asadurian, Helena Kurilin, Hava Lichtig, et al.
Health Care for Women International|November 7, 2014
Strategies for Increasing Cervical Cancer Screening Amongst First Nations Communities in Northwest Ontario, CanadaMarion Maar, Pamela Wakewich, Brianne Wood, et al.
Laboratory Investigation; a Journal of Technical Methods and Pathology|May 19, 2010
IFN-κ, a novel type I IFN, is undetectable in HPV-positive human cervical keratinocytesCorrene A DeCarlo, Alberto Severini, Lutz Edler, et al.
Pageof 6